Safety of Collagenase Clostridium histolyticum Injection Therapy for Peyronie Disease in Patients Continuing Antiplatelet or Anticoagulant Therapy.
暂无分享，去创建一个
[1] J. Mills,et al. A modified technique for intralesional injection of collagenase Clostridium histolyticum for Peyronie’s disease results in reduced procedural morbidity using a standardized hematoma classification rubric , 2019, World Journal of Urology.
[2] M. Butaney,et al. Variation in collagenase Clostridium histolyticum practice patterns: a Survey of ISSM Members , 2019, International Journal of Impotence Research.
[3] L. Levine,et al. Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie's disease: a phase 3 open-label study. , 2015, The journal of sexual medicine.
[4] A. Gross,et al. Anticoagulation and antiplatelet therapy in urological practice: ICUD/AUA review paper. , 2014, The Journal of urology.
[5] I. Goldstein,et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. , 2013, The Journal of urology.
[6] F. Burzotta,et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. , 2006, European heart journal.